Q1 Earnings Estimate for DYN Issued By HC Wainwright

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Dyne Therapeutics in a report issued on Tuesday, March 3rd. HC Wainwright analyst A. Ghosh expects that the company will earn ($0.76) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q2 2026 earnings at ($0.76) EPS and Q3 2026 earnings at ($0.76) EPS.

Several other research analysts have also commented on DYN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, January 21st. Chardan Capital restated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday. Wall Street Zen downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 28th. Morgan Stanley lowered their price objective on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Royal Bank Of Canada lifted their price objective on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.00.

Dyne Therapeutics Stock Up 4.3%

Dyne Therapeutics stock opened at $15.23 on Thursday. The company has a market capitalization of $2.51 billion, a P/E ratio of -4.30 and a beta of 1.34. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.47 and a current ratio of 22.25. Dyne Therapeutics has a fifty-two week low of $6.36 and a fifty-two week high of $25.00. The stock has a 50-day simple moving average of $17.26 and a 200-day simple moving average of $17.04.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new stake in shares of Dyne Therapeutics during the 1st quarter worth about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after acquiring an additional 2,886 shares during the period. Goldman Sachs Group Inc. raised its holdings in Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after acquiring an additional 366,183 shares during the last quarter. Caxton Associates LLP purchased a new position in shares of Dyne Therapeutics during the 1st quarter worth $157,000. Finally, CWM LLC lifted its stake in shares of Dyne Therapeutics by 168.1% during the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after purchasing an additional 1,900 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.